Bullimore MA, Brennan NA. The underestimated role of myopia in uncorrectable visual impairment in the United States. Sci Rep. 2023;13:15283.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tideman JWL, Snabel MCC, Tedja MS, Van Rijn GA, Wong KT, Kuijpers RAM, et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355–63.

Article  PubMed  Google Scholar 

Haarman AEG, Enthoven CA, Willem Tideman JL, Tedja M, Verhoeven VJM, Klaver CW. The complications of myopia: a review and meta-analysis. Invest Ophthalmol Vis Sci. 2020;61:49.

Article  PubMed  PubMed Central  Google Scholar 

Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123:1036–42.

Article  PubMed  Google Scholar 

Wu JF, Bi HS, Wang SM, Hu YY, Wu H, Sun W, et al. Refractive error, visual acuity and causes of vision loss in children in Shandong, China. The Shandong Children Eye Study. PLoS One. 2013;8:e82763.

Article  PubMed  PubMed Central  Google Scholar 

Sun J, Zhou J, Zhao P, Lian J, Zhu H, Zhou Y, et al. High prevalence of myopia and high myopia in 5060 Chinese University students in Shanghai. Invest Ophthalmol Vis Sci. 2012;53:7504–9.

Article  PubMed  Google Scholar 

Zhao J, Xu X, Ellwein LB, Guan H, He M, Liu P, et al. Causes of visual impairment and blindness in the 2006 and 2014 nine-province surveys in rural China. Am J Ophthalmol. 2019;197:80–7.

Article  PubMed  Google Scholar 

Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control. Prog Retin Eye Res. 2020;83:100923.

Article  PubMed  Google Scholar 

Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119:347–54.

Article  PubMed  Google Scholar 

Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, et al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113:2285–91.

Article  PubMed  Google Scholar 

Chia A, Lu Q-S, Tan D. Five-year clinical trial on Atropine for the Treatment Of Myopia 2: myopia control with atropine 0.01% eyedrops. Ophthalmology. 2016;123:391–9.

Article  PubMed  Google Scholar 

Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, et al. Three-year clinical trial of Low-concentration Atropine for Myopia Progression (LAMP) study: continued versus washout: phase 3 report. Ophthalmology. 2022;129:308–21.

Article  PubMed  Google Scholar 

Yam JC, Jiang Y, Tang SM, Law AKPP, Chan JJ, Wong E, et al. Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126:113–24.

Article  PubMed  Google Scholar 

Loughman J, Kobia-Acquah E, Lingham G, Butler J, Loskutova E, Mackey DA, et al. Myopia outcome study of atropine in children: two-year result of daily 0.01% atropine in a European population. Acta Ophthalmol. 2023;102:e245–56.

PubMed  Google Scholar 

Lee SS-Y, Lingham G, Blaszkowska M, Sanfilippo PG, Koay A, Franchina M, et al. Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: a randomised clinical trial. Clin Exp Ophthalmol. 2022;50:1001–12.

Article  PubMed  PubMed Central  Google Scholar 

Zadnik K, Schulman E, Flitcroft I, Fogt JS, Blumenfeld LC, Fong TM, et al. Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial. JAMA Ophthalmol. 2023;141:990–9.

Repka MX, Weise KK, Chandler DL, Wu R, Melia BM, Manny RE, et al. Low-dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial. JAMA Ophthalmol. 2023;141:756–65.

Article  PubMed  PubMed Central  Google Scholar 

Salazar M, Shimada K, Patil PN. Iris pigmentation and atropine mydriasis. J Pharmacol Exp Ther. 1976;197:79–88.

Article  CAS  PubMed  Google Scholar 

German EJ, Wood D, Hurst MA. Ocular effects of antimuscarinic compounds: is clinical effect determined by binding affinity for muscarinic receptors or melanin pigment? J Ocul Pharmacol Ther. 1999;15:257–69.

Article  CAS  PubMed  Google Scholar 

Lovasik JV. Pharmacokinetics of topically applied cyclopentolate HCI and tropicamide. Optom Vis Sci. 1986;63:787–803.

Article  CAS  Google Scholar 

Mackey DA, Wilkinson CH, Kearns LS, Hewitt AW. Classification of iris colour: review and refinement of a classification schema. Clin Exp Ophthalmol. 2011;39:462–71.

Article  PubMed  Google Scholar 

Loughman J, Lingham G, Nkansah EK, Kobia-Acquah E, Flitcroft DI. Efficacy and safety of different atropine regimens for the treatment of myopia in children. JAMA Ophthalmol. 2025;143:134–44.

Atlasik B, Stepien K, Wilczok T. Interaction of drugs with ocular melanin in vitro. Exp Eye Res. 1980;30:325–31.

Article  CAS  PubMed  Google Scholar 

Upadhyay A, Beuerman RW. Biological mechanisms of atropine control of myopia. Eye Contact Lens. 2020;46:129–35.

Article  PubMed  PubMed Central  Google Scholar 

Kumar P, Saxena R, Dhiman R, Phuljhele S, Kumar V, Chawla R, et al. Evaluation of the levels of low-dose topical atropine (0.01%) in aqueous and vitreous humor in human eyes. Optom Vis Sci. 2023;100:530–6.

Article  PubMed  Google Scholar 

Wei S, Li SM, An W, Du J, Liang X, Sun Y, et al. Myopia progression after cessation of low-dose atropine eyedrops treatment: A two-year randomized, double-masked, placebo-controlled, cross-over trial. Acta Ophthalmol. 2023;101:e177–84.

Article  CAS  PubMed  Google Scholar 

Hieda O, Hiraoka T, Fujikado T, Ishiko S, Hasebe S, Torii H, et al. Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn J Ophthalmol. 2021;65:315–25.

Article  CAS  PubMed  Google Scholar 

Saxena R, Dhiman R, Gupta V, Kumar P, Matalia J, Roy L, et al. Atropine for the treatment of childhood myopia in India: multicentric randomized trial. Ophthalmology. 2021;128:1367–9.

Article  PubMed  Google Scholar 

Iribarren R, Cunha C, Kaymak H, Grzybowski A. Preservatives and pH in low-dose atropine formulations for clinical trials. Acta Ophthalmol. 2024;102:364–6.

Article  CAS  PubMed  Google Scholar 

Austermann H, Schaeffel F, Mathis U, Hund V, Mußhoff F, Ziemssen F, et al. Corneal penetration of low-dose atropine eye drops. J Clin Med. 2021;10:588.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei S, Li SM, An W, Du J, Liang X, Sun Y, et al. Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children a randomized clinical trial. JAMA Ophthalmol. 2020;138:1178–84.

Article  PubMed  PubMed Central  Google Scholar 

Cyphers B, Huang J, Walline JJ. Symptoms and ocular findings associated with administration of 0.01% atropine in young adults. Clin Exp Optom. 2023;106:311–21.

Article  PubMed  Google Scholar 

Kaymak H, Fricke A, Mauritz Y, Löwinger A, Klabe K, Breyer D, et al. Short-term effects of low-concentration atropine eye drops on pupil size and accommodation in young adult subjects. Graefes Arch Clin Exp Ophthalmol. 2018;256:2211–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joachimsen L, Farassat N, Bleul T, Böhringer D, Lagrèze WA, Reich M. Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: a pilot study. Int Ophthalmol. 2021;41:2001–8.

Article  PubMed  PubMed Central